Počet záznamů: 1
Inclusivity and diversity: Integrating international perspectives on stem cell challenges and potential
- 1.
SYSNO ASEP 0544794 Druh ASEP J - Článek v odborném periodiku Zařazení RIV Záznam nebyl označen do RIV Poddruh J Článek ve WOS Název Inclusivity and diversity: Integrating international perspectives on stem cell challenges and potential Tvůrce(i) Fears, R. (IT)
Akutsu, H. (JP)
Alentajan-Aleta, L.T. (PH)
Caicedo, A. (EC)
Campos de Carvalho, A.C. (BR)
Čolić, M. (RS)
Cornish, J. (NZ)
Cossu, G. (GB)
Debré, P. (FR)
Dierckxsens, Geoffrey (FLU-F) ORCID, RID, SAI
El-Badri, N. (EG)
Griffin, G. (GB)
Chingo-Ho Hsieh, P. (TW)
Inamdar, M.S. (IN)
Kumar, P. (ZA)
Abraham, C.M. (CU)
Maciulaitis, R. (LT)
Al Mahtab, M. (BD)
O’Brien, F.J. (IE)
Pepper, M.S. (ZA)
Meulen, V.T. (IT)Zdroj.dok. Stem Cell Reports. - : Cell Press - ISSN 2213-6711
Roč. 16, č. 8 (2021), s. 1847-1852Poč.str. 6 s. Forma vydání Tištěná - P Jazyk dok. eng - angličtina Země vyd. US - Spojené státy americké Klíč. slova biomedical policy ; global ; regenerative medicine ; stem cells Vědní obor RIV AA - Filosofie a náboženství Obor OECD Philosophy, History and Philosophy of science and technology Způsob publikování Open access Institucionální podpora FLU-F - RVO:67985955 UT WOS 000684300500002 EID SCOPUS 85112133403 DOI 10.1016/j.stemcr.2021.07.003 Anotace Regenerative medicine has great potential. The pace of scientific advance is exciting and the medical opportunities for regeneration and repair may be transformative. However, concerns continue to grow, relating to problems caused both by unscrupulous private clinics offering unregulated therapies based on little or no evidence and by premature regulatory approval on the basis of insufficient scientific rationale and clinical evidence. An initiative by the InterAcademy Partnership convened experts worldwide to identify opportunities and challenges, with a focus on stem cells. This was designed to be inclusive and consensus outputs reflected the diversity of the global research population. Among issues addressed for supporting research and innovation while protecting patients were ethical assessment, pre-clinical and clinical research, regulatory authorization and medicines access, and engagement with patients, policy makers, and the public. The InterAcademy Partnership (IAP) identified options for action for sharing good practice and building collaboration within the scientific community and with other stakeholders worldwide. Pracoviště Filosofický ústav Kontakt Chlumská Simona, chlumska@flu.cas.cz ; Tichá Zuzana, asep@flu.cas.cz Tel: 221 183 360 Rok sběru 2022
Počet záznamů: 1